Pregnancy Biomarker Monitoring: Can Wearables Spot Risk Earlier?

Pregnancy biomarker monitoring is moving beyond occasional clinic measurements toward continuous signals captured by wearable devices. A recent patent filing describes a system intended to track pulse wave velocity, blood pressure and arterial stiffness, with the aim of identifying changes associated with hypertensive disorders and other pregnancy complications.

That prospect is clinically important because pregnancy physiology can change quickly, while warning signs may emerge between appointments or after delivery. Yet a patent is not proof that a wearable can diagnose preeclampsia, gestational hypertension or gestational diabetes. The useful question is not whether a device collects more data, but whether its measurements are accurate in pregnant populations and lead to timely, appropriate care.

What pregnancy biomarker monitoring could measure

Blood pressure remains one of the most important biomarkers in pregnancy. New or worsening hypertension can indicate gestational hypertension or preeclampsia, particularly when it occurs alongside protein in the urine, abnormal laboratory findings, severe headache, visual disturbance, upper abdominal pain, breathlessness or sudden swelling. A single normal reading cannot exclude a condition that develops later.

Pulse wave velocity estimates how quickly the pressure wave generated by each heartbeat travels through the arteries. Faster transmission generally corresponds to greater arterial stiffness. Pregnancy changes the cardiovascular system substantially, so interpreting this signal requires pregnancy-specific reference ranges rather than thresholds developed in non-pregnant adults.

Wearables may infer vascular information from optical pulse sensors, timing measurements and algorithms rather than measuring blood pressure directly with an inflatable cuff. That distinction matters. A smooth trend displayed by an app may still be an estimate affected by movement, skin contact, device position, temperature and the model used to translate sensor data into a physiological value.

Gestational diabetes presents another challenge. It is diagnosed through glucose testing, not arterial stiffness alone. Cardiovascular trends might eventually contribute to broader risk models, but they cannot currently replace established glucose screening.

Pregnancy biomarker monitoring needs clinical validation

A useful maternity wearable must clear several hurdles. It needs to measure accurately across different skin tones, body sizes, stages of pregnancy, underlying health conditions and levels of swelling. Performance should also be tested during ordinary daily life, not only under controlled laboratory conditions.

Researchers then need to establish whether a change is clinically meaningful. Pregnancy does not have one fixed cardiovascular baseline. Heart rate, blood volume, vascular resistance and sleep can shift across trimesters. An algorithm must distinguish expected adaptation from a pattern that warrants assessment without creating excessive false alarms.

The most consequential test is whether monitoring improves outcomes. Earlier alerts are valuable only if they prompt confirmatory measurement, clinical review and effective treatment. Poorly calibrated alerts could increase anxiety and unnecessary visits, while false reassurance could delay care.

The current report concerns a patent filing, not a completed clinical trial or an approved diagnostic product. It signals a possible direction for wearable technology, but evidence on sensitivity, specificity, safety and real-world benefit has not yet been presented in the supplied reporting.

Autoimmune disease can change the meaning of pregnancy signals

New research also highlights how baseline health can alter pregnancy monitoring needs. Investigators studying women with inflammatory arthritis and lupus report that pregnancy places an additional burden on an immune system already managing autoimmune disease. The immune system must tolerate fetal tissue while continuing to defend against infection, creating a particularly complex balance when inflammatory pathways are dysregulated.

For these women, cardiovascular and symptom data cannot be interpreted in isolation. Blood pressure changes, fatigue, pain, swelling and laboratory markers may reflect pregnancy adaptation, an autoimmune flare, medication changes, infection or an obstetric complication. Lupus is also associated with higher risks of hypertensive pregnancy disorders in some patients, making coordinated specialist care especially important.

This illustrates a broader limitation of consumer biomarker systems: context determines meaning. An elevated resting heart rate after poor sleep is different from a persistent increase accompanied by fever or breathlessness. Swelling can be common in late pregnancy, but sudden swelling with headache or visual symptoms requires a different response. Algorithms designed around an “average” pregnancy may perform less reliably in people with complex conditions unless those groups are adequately represented during development and validation.

The postpartum period is part of the monitoring window

Maternal risk does not end at delivery. Hospitals in the United States are using simple wristbands printed with “I Gave Birth” to help clinicians recognise that a patient is recently postpartum. The intervention is not a biomarker device, but it addresses the same problem of context: symptoms and vital signs can be misinterpreted if recent pregnancy is not immediately visible to emergency or urgent-care staff.

Postpartum preeclampsia can occur after birth, including in people who did not receive a preeclampsia diagnosis during pregnancy. Persistent high blood pressure, severe headache, vision changes, chest pain, shortness of breath, seizures, heavy bleeding, fever, or one-sided leg pain and swelling require prompt medical assessment. A wearable alert should never be treated as the sole gatekeeper for seeking care, and the absence of an alert does not rule out a complication.

Continuous technology may eventually help bridge gaps between discharge and follow-up, but low-tech identification, access to validated cuffs, clear escalation pathways and clinical responsiveness remain fundamental. Monitoring without a reliable route to care is incomplete.

Turning repeated measurements into useful patterns

The strongest potential of wearable pregnancy data lies in change over time. A personal baseline may help reveal sustained shifts that a single measurement misses, but only when the underlying sensor is sufficiently accurate and the data are interpreted alongside symptoms, gestational stage, medical history and confirmatory clinical tests.

For now, validated blood pressure measurement and recommended antenatal screening remain the standard. Emerging measures such as pulse wave velocity are promising research signals rather than standalone diagnostic answers. Regulation, independent validation and transparent reporting across diverse pregnant populations will determine whether continuous monitoring becomes clinically useful.

Blood pressure, sleep quality, energy, swelling and other pregnancy or postpartum symptoms become more readable when logged consistently over weeks. This is the kind of pattern Tulsy is built to surface.

Sources: FemTech Insider, Medical Xpress.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.